In another example of the volatility facing developers of obesity drugs, Veru saw its share price cut nearly in half – despite reporting ostensibly positive data for a drug candidate. Veru's enobosarm ...

The UK-US deal does not resolve every challenge – no single agreement could. But it marks a meaningful step toward restoring ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singaporean Health Sciences Authority (HSA) say the ...

Drug delivery is no longer just about convenience. It’s about enabling the therapies of the future to succeed where they ...

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series ...

The UK government has confirmed that the rebate rate for newer medicines supplied to the NHS under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) will be 14.5% next year, ...

Regeneron has been a bit of a latecomer in the market for BCMA-directed therapies for multiple myeloma, but is pushing to catch up with rival therapies from Johnson & Johnson and Pfizer. At ASH, ...

Less than two years after buying Chinese biotech Gracell for its cell therapy platform, AstraZeneca has reported encouraging clinical results with the lead CAR-T from the deal, GC012F (now AZD0120), ...

An artificial intelligence-powered digital health worker has been unveiled by the World Health Organisation (WHO) as its latest tool for disseminating reliable health information to the public.

A court in Munich has granted a preliminary injunction that will prevent MSD from distributing the subcutaneous version of its cancer immunotherapy Keytruda in the German market. The verdict is the ...